Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CYBN SEC filings page on Stock Titan aggregates Cybin Inc.’s regulatory disclosures as a foreign issuer, giving investors structured access to the company’s official documents. Cybin files with the U.S. Securities and Exchange Commission primarily on Form 40-F and Form 6-K, and also uses Form 25 for listing changes. These filings are central to understanding the company’s clinical-stage neuropsychiatry business, its capital structure, and its transition between stock exchanges.
Form 6-K submissions for Cybin typically include interim consolidated financial statements, management’s discussion and analysis, certifications of interim filings, and news releases. Many 6-Ks also incorporate material change reports, equity distribution agreements, and prospectus-related documents by reference into Cybin’s registration statements on Form F-10. For a company developing drug candidates such as CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, these filings provide context on how clinical programs are funded and governed.
The filings page also features Cybin’s Form 25, which notifies the SEC of the voluntary removal of its common shares from listing and registration on the NYSE American. This document confirms that the company has complied with the exchange’s rules and the requirements for voluntary withdrawal, and it aligns with Cybin’s news release describing its plan to transfer its U.S. listing to the Nasdaq Global Market and to change its trading symbol from CYBN to HELP.
On Stock Titan, each new Cybin filing from EDGAR is captured and presented with AI-powered summaries that explain the purpose and key points of documents such as 6-Ks, F-10 registration statements, and the Form 25 delisting notice. This helps readers quickly understand how Cybin reports its financial results, documents material changes, and manages its listing status, while still allowing direct access to the underlying SEC filings for detailed review.
CYBIN Inc. is offering securities via a secondary prospectus supplement and outlines risks, regulatory constraints and clinical-development milestones. The document emphasizes that the company currently does not handle controlled or restricted substances under Canadian or U.S. law and only works with psychedelic compounds within approved laboratory and clinical-trial frameworks or via third parties where required. Key near-term development objectives include topline efficacy readout from the first Phase 3 study (APPROACH) and progression of two additional Phase 3 studies (EMBRACE, EXTEND) for the deuterated psilocin program (CYB003), completion and topline data from a Phase 2 GAD study for deuterated DMT (CYB004), and delivery of a drug development candidate for the phenethylamine/tryptamine derivatives program (CYB005). The prospectus warns of continuing substantial losses, pandemic risks, potential clinical-trial delays, reliance on key personnel, and regulatory changes across multiple jurisdictions.
CYBIN Inc. discloses risks around a proposed secondary offering, including uncertainty in raising additional funding and continued substantial losses. The company emphasizes regulatory constraints on psychedelic substances in key jurisdictions and states it currently does not handle controlled substances outside approved laboratory or clinical trial settings. Clinical development milestones are outlined: Phase 3 topline readout for deuterated psilocin (CYB003) and progression of two additional Phase 3 studies, a Phase 2 completion and topline readout for deuterated DMT (CYB004), and delivery of a drug development candidate from the CYB005 program. Proceeds are intended for working capital and general corporate purposes.
Cybin Inc. filed a Form D for a Rule 506(b) exempt securities offering to permit exercise of stock options that could generate up to $288,280 USD (CAD conversion provided). The securities are stock options exercisable at CAD$10.00 per share that vest in eight quarterly tranches beginning September 30, 2025. The filing reports 0 amount sold to date, 288,280 USD remaining to be sold, and 10 total investors (also listed as 10 non-accredited investors). The offering is intended to last more than one year, minimum investment accepted is $0 USD, and no sales commissions or finders' fees are reported.
CYBIN INC. filed a Form D notice reporting a Regulation D exempt offering of options. The filing states a total potential offering amount of $637,404 USD (maximum proceeds from option exercises) and that $0 has been sold to date. The securities are stock options exercisable at CAD$11.00 per share that vest in eight quarterly tranches beginning September 30, 2025. The issuer selected Rule 506(b) as the exemption and indicated the offering may last more than one year. The Form D lists two investors in the offering, both non-accredited, and discloses no sales commissions or finders' fees and $0 proposed for payments to named executives or directors.